RESPREEZA

This brand name is authorized in Austria, Croatia, Cyprus, Estonia, France, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug RESPREEZA contains one active pharmaceutical ingredient (API):

1	Alfa1 antitrypsin UNII F43I396OIS - .ALPHA.1-PROTEINASE INHIBITOR HUMAN
	Human alpha1-proteinase inhibitor is understood to be the primary anti-protease in the lower respiratory tract, where it inhibits neutrophil elastase (NE). Normal healthy individuals produce sufficient alpha1-proteinase inhibitor to control the NE produced by activated neutrophils and are thus able to prevent inappropriate proteolysis of lung tissue by NE.
	Read more about Alfa1 antitrypsin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RESPREEZA Powder and solvent for solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02AB02	Alfa1 antitrypsin	B Blood and blood forming organs → B02 Antihemorrhagics → B02A Antifibrinolytics → B02AB Proteinase inhibitors
Discover more medicines within B02AB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1695045, 1789173, 1789184
ES	Centro de información online de medicamentos de la AEMPS	1151006001, 1151006002, 1151006003
FR	Base de données publique des médicaments	64642836, 65543887, 68323818
GB	Medicines & Healthcare Products Regulatory Agency	346063
IT	Agenzia del Farmaco	044479018, 044479020, 044479032
LT	Valstybinė vaistų kontrolės tarnyba	1077846, 1086931, 1086932
NL	Z-Index G-Standaard, PRK	129828, 167622, 167649
PL	Rejestru Produktów Leczniczych	100354887, 100417872, 100417889
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63059001